Viokace FDA Approval History
FDA Approved: Yes (First approved March 1, 2012)
Brand name: Viokace
Generic name: pancrelipase
Dosage form: Tablets
Company: Allergan plc
Treatment for: Pancreatic Exocrine Dysfunction
Viokace (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases. Viokace, in combination with a proton pump inhibitor, is indicated in adults for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy.
Development timeline for Viokace
| Date | Article |
|---|---|
| Mar 1, 2012 | Approval Aptalis Pharma Announces FDA Approval of Viokace (Pancrelipase) Tablets |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
